ANI Pharmaceuticals ANIP 深 沪
已收盘 10-02 16:00:00 美东时间
72.18
-0.780
-1.07%
华盛通- 最 高73.27
- 今 开73.16
- 成交量 30.95万股
- 最 低 71.73
- 昨 收 72.96
- 总市值 16.58亿
- 52周最高 97.00
- 市盈率 静 21.71
- 换手率 1.35%
- 52周最低 69.58
- 委 比 -32.34%
- 总股本 2297.04万
- 历史最高 99.50
- 量 比 0.89
- 振 幅 2.11%
- 历史最低 0.80
- 每 手 1
- 风险率 5.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
ANI Pharmaceuticals Receives Final FDA Approval Of Its Abbreviated New Drug Application For Everolimus Tablets For Oral Suspension
Approval for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI’s Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz®. "The FDA approval of Everolimus Tablets for Suspension is another example of our R&D team's continued execu...
09-23 18:56
ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension
ANI Pharmaceuticals received FDA approval for its generic version of Everolimus Tablets for Oral Suspension, marking another success for its R&D team. The product is expected to boost the company's generics portfolio, with U.S. annual sales of approximately $123 million. ANI aims to launch at least 15 new generics this year, reflecting strong performance in its U.S.-focused generics business.
09-23 10:55
ANI Pharmaceuticals to Present at September Investor Conferences
ANI Pharmaceuticals announced that its CEO, Nikhil Lalwani, and executives will participate in fireside chats at three upcoming investor conferences: the 2026 Wells Fargo Healthcare Conference on September 10, 2026, at 1:30 p.m. ET; the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, at 7:00 a.m. ET; and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, at 12:00 p.m. ET. Webcasts fo...
09-03 10:55
ANI Pharmaceuticals reshapes board to advance rare disease strategy
The latest update is out from ANI Pharmaceuticals ( ($ANIP) ). On August 19, 20...
08-24 19:48
ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors
ANI Pharmaceuticals appoints Henry Gosebruch to its Board of Directors, leveraging his 30+ years of experience in biopharmaceutical strategy, business development, and finance to accelerate its transformation into a leading Rare Disease company. Gosebruch, formerly CEO of Lakefront Biotherapeutics and AbbVie's Chief Strategy Officer, will support ANI's growth initiatives. Samy Shanmugam resigns from the Board but remains in his executive role.
08-24 10:55
美股大行评级 | Take-Two、Csquare、Standard获多家大行首予买入评级！潜在涨幅215.32%！HC Wainwright.升Innate Pharma(IPHA)目标价至7美元
今日重点评级关注：HC Wainwright & Co.：维持Innate Pharma"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从20美元升至25美元
08-11 11:45
ANI Pharmaceuticals shares are trading lower despite reporting better-than-expected Q2 results, possibly dragged down by lowered Cortrophin outlook, margin compression, and rising costs.
ANI Pharmaceuticals shares are trading lower despite reporting better-than-expected Q2 results, possibly dragged down by lowered Cortrophin outlook, margin compression, and rising costs.
08-08 02:26
财报速睇 | ANI Pharmaceuticals 2026财年Q2营收2.66亿美元，同比增长25.9%；归母净利润0.25亿美元，同比增长203.5%
华盛资讯8月7日讯，ANI Pharmaceuticals公布2026财年Q2业绩，公司Q2营收2.66亿美元，同比增长25.9%，归母净利润0.25亿美元，同比增长203.5%。
08-07 19:25
财报速睇 | ANI Pharmaceuticals 2026财年Q2营收2.66亿美元，同比增长25.9%；归母净利润0.25亿美元，同比增长203.5%
华盛资讯8月7日讯，ANI Pharmaceuticals公布2026财年Q2业绩，公司Q2营收2.66亿美元，同比增长25.9%，归母净利润0.25亿美元，同比增长203.5%。
08-07 19:21
